ChromaDex Corporation (CDXC)

Market Cap	246.38M
Revenue (ttm)	83.17M
Net Income (ttm)	-3.53M
Shares Out	75.54M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	323.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	238,801
Open	3.500
Previous Close	3.480
Day's Range	3.250 - 3.540
52-Week Range	1.250 - 4.650
Beta	1.96
Analysts	Strong Buy
Price Target	6.00 (+81.82%)
Earnings Date	May 8, 2024

About CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufactur...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Robert N. Fried
• Employees: 106
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXC

Financial Performance

In 2023, ChromaDex's revenue was $83.57 million, an increase of 15.99% compared to the previous year's $72.05 million. Losses were -$4.94 million, -70.15% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CDXC stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 81.82% from the latest price.

Price Target

$6.0

(81.82% upside)

Analyst Consensus: Strong Buy